Arca
Skip to content
Tools
Tools

Transthyretin mRNA

Nucleic acid in Homo sapiens that 8 drugs act on.

  • Drugs that act on it: 8
  • Approved: 5
  • In phases 1 to 3: 3
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Other 8

Approved5

  • Vutrisiran
  • Inotersen
  • Eplontersen sodium
  • Patisiran sodium
  • Vutrisiran sodium

Phase 33

  • Eplontersen
  • Patisiran
  • Revusiran

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      VutrisiranApprovedAlnylam PharmaceuticalsOligonucleotideRnai inhibitorTransthyretin mRNA rnai inhibitor4
      InotersenBoxed warningApprovedIonis PharmaceuticalsOligonucleotideAntisense inhibitorTransthyretin mRNA antisense inhibitor1
      Eplontersen sodiumApprovedAstraZeneca PharmaceuticalsOligonucleotideAntisense inhibitorTransthyretin mRNA antisense inhibitor0
      Patisiran sodiumApprovedAlnylam PharmaceuticalsOligonucleotideRnai inhibitorTransthyretin mRNA RNAi inhibitor0
      Vutrisiran sodiumApprovedAlnylam PharmaceuticalsOligonucleotideRnai inhibitorTransthyretin mRNA rnai inhibitor0
      EplontersenPhase 3AstraZeneca PharmaceuticalsOligonucleotideAntisense inhibitorTransthyretin mRNA antisense inhibitor7
      PatisiranPhase 3Alnylam PharmaceuticalsOligonucleotideRnai inhibitorTransthyretin mRNA RNAi inhibitor2
      RevusiranPhase 3Alnylam PharmaceuticalsOligonucleotideRnai inhibitorTransthyretin mRNA RNAi inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
      Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired SubpopulationsEplontersen—RecruitingAstraZenecaJun 17, 2026
      A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CMEplontersenPhase 2Active, not recruitingAstraZenecaMay 27, 2026
      TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyVutrisiranPhase 3RecruitingAlnylam PharmaceuticalsOct 31, 2025
      The Eplontersen Pregnancy and Lactation Outcomes StudyEplontersen—RecruitingAstraZenecaOct 3, 2025
      A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyVutrisiranPhase 3Enrolling by invitationAlnylam PharmaceuticalsNov 8, 2024
      Non-interventional Study of Patients With Transthyretin (ATTR) AmyloidosisEplontersen—RecruitingAstraZenecaJun 20, 2024
      EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid CardiomyopathyEplontersenPhase 3Active, not recruitingAstraZenecaJan 8, 2024
      Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or VutrisiranPatisiran, Vutrisiran—Active, not recruitingRennes University HospitalMay 24, 2023
      An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)EplontersenPhase 3Enrolling by invitationIonis Pharmaceuticals, Inc.Dec 28, 2022
      A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid PolyneuropathyEplontersenPhase 3Active, not recruitingIonis Pharmaceuticals, Inc.Oct 8, 2021
      Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance ProgramPatisiran—RecruitingAlnylam PharmaceuticalsSep 10, 2021
      TEGSEDI Pregnancy Surveillance ProgramInotersen—Not yet recruitingAkcea TherapeuticsFeb 17, 2020
      HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyVutrisiranPhase 3Active, not recruitingAlnylam PharmaceuticalsNov 6, 2019

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4296221, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.